Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [T cells]

ABSTRACT: Despite the remarkable successes of cancer immunotherapies, the majority of patients do not exhibit durable responses. While treatment resistance has frequently been attributed to clonal selection and immunoediting, currently, little evidence directly demonstrates this process in epithelial cancers. Here, we demonstrate in both mouse models and human cells, that tumor cells evade immunotherapy by generating transient cell-in-cell structures, which are impenetrable to immune-derived cytotoxic compounds and to chemotherapies. This formation is mediated predominantly by DLL4/DLL1 which are elevated on activated T cells and along with IFNg induces STAT3 phosphorylation in tumors cells. In contrast to previous reports on cell-in-cell formations, here both cells remain alive and disseminate into single tumor cells once T cells are no longer present. Overall, this work highlights a previously unknown resistance mechanism which enable tumor cells to survive immune pressure and provides a new theoretical framework to cancer immunotherapies.

ORGANISM(S): Mus musculus

PROVIDER: GSE164076 | GEO | 2020/12/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy [B16F10]

Project description:Despite the remarkable successes of cancer immunotherapies, the majority of patients do not exhibit durable responses. While treatment resistance has frequently been attributed to clonal selection and immunoediting, currently, little evidence directly demonstrates this process in epithelial cancers. Here, we demonstrate in both mouse models and human cells, that tumor cells evade immunotherapy by generating transient cell-in-cell structures, which are impenetrable to immune-derived cytotoxic compounds and to chemotherapies. This formation is mediated predominantly by DLL4/DLL1 which are elevated on activated T cells and along with IFNg induces STAT3 phosphorylation in tumors cells. In contrast to previous reports on cell-in-cell formations, here both cells remain alive and disseminate into single tumor cells once T cells are no longer present. Overall, this work highlights a previously unknown resistance mechanism which enable tumor cells to survive immune pressure and provides a new theoretical framework to cancer immunotherapies.

2020-12-31 | GSE164075 | GEO

ATAC sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

Project description:Several genes like Nfkb, Npy and Dll1 showed altered enrichment peaks between Dll1+ and Dll1- population of tumor cells.

2020-11-20 | GSE133736 | GEO

RNA sequence analysis to compare MMTV-PyMT tumor cells with and without Dll1

Project description:Several cell cycle genes were altered between Dll1+ and Dll1- population of tumor cells

2020-11-20 | GSE129198 | GEO

Activity of the mouse Notch ligand DLL1 is sensitive to C-terminal tagging in vivo

Project description:Objective DLL1 is a mammalian Notch ligand with essential functions during embryonic development. We tagged endogenous DLL1 in one homologous recombination step such that AcGFP-HA tagged DLL1 could be converted by Cre-mediated site-specific recombination into StrepFlag tagged DLL1. We anticipated that this should allow us to visualise DLL1 in living cells as well as allow for sorting and enrichment of DLL1-expressing cells and efficient purification of DLL1 protein complex. Results We generated constructs to express a DLL1 variant that carried C-terminal in frame an AcGFPHA tag flanked by loxP sites followed by a StrepFlag tag out of frame. Cre-mediated recombination removed AcGFP-HA and added StrepFlag in frame to DLL1. The AcGFPHAstopStrepFlag tag was added to the Dll1 cDNA to allow for tests in cultured cells in vitro and was introduced into endogenous DLL1 in mice using ES cells modified by homologous recombination. Tagged DLL1 protein was detected by antibodies against GFP and HA or Flag, respectively, both in CHO cell and embryo lysates. In CHO cells the AcGFP protein fused to DLL1 was functional. In vivo AcGFP expression was below the level of detection by direct fluorescence. However, the StrepFlag tag allowed us to specifically purify DLL1 complexes from embryo lysates. Homozygous mice expressing AcGFPHA or StrepFlag-tagged DLL1 revealed a vertebral column phenotype reminiscent of disturbances in AP polarity during somitogenesis, a process most sensitive to reduced DLL1 function. Thus, even small C-terminal tags can impinge on sensitive developmental processes requiring DLL1 activity.

2021-11-03 | PXD024680 | Pride

Identification of Notch ligand useage by splenic B cells using Dll1 and Dll4 Notch ligand blockade.

Project description:Marginal zone (MZ) B cells leverage Notch2 signals to attain rapid differentiation responses and positional cues with in the spenic environment.To determine the likely molecular source of Notch2 signals we sought to block the Notch ligands delta-like ligand 1 (Dll1) and delta-like ligand 4 (Dll4) in wildtype mice using in-vivo treatment with monoclonal blocking antibodies. Splenic populations of MZ B cells and follicular B cells were sort purified after 12, 24 and 48 hours of blockade and analyzed by RNA-seq.

2024-10-18 | GSE274991 | GEO

Mapping of immunopeptidome of cancer immunotherapy with oncolytic virus and checkpoint blockade

Project description:The elucidation of therapy-induced changes to the class I major histocompatibility complex (MHC-I)-bound tumor antigens is crucial for understanding immune-mediated tumor eradication and identifying potential targets for peptide vaccines to enhance the efficacy of immunotherapies. Here, we investigated how oncolytic reovirus therapy with and without immune checkpoint blockade (ICB) alters the tumor peptide-MHC repertoire. Using mass spectrometry analysis of immunoaffinity purified MHC peptides, we first showed that changes to the MHC immunopeptidome following reovirus treatment is cancer type-dependent, where a murine fibrosarcoma model displayed quantitative and qualitative variance in differentially expressed peptides (DEPs) as compared to those identified in a murine ovarian cancer model. We then determined that the combination therapy of reovirus and ICB in the fibrosarcoma model resulted in higher numbers of DEPs relative to either monotherapy alone. Most importantly, we identified reovirus and ICB-induced MHC peptides that are biologically active in stimulating interferon-gamma response in cognate CD8+ T cells, which likely contribute to cancer immunoediting. These findings highlight the importance of therapy-induced changes to the MHC immunopeptidome in shaping the underlying anti-tumor immune responses during reovirus and ICB combination therapy.

2021-12-06 | PXD024369 | Pride

Identification of Notch ligand useage by splenic B cells using Dll1 and Dll4 Notch ligand blockade.

Project description:Identification of Notch ligand useage by splenic B cells using Dll1 and Dll4 Notch ligand blockade.

| PRJNA1148919 | ENA

Immunoediting instructs tumor metabolic reprogramming to support immune evasion [smartseq]

Project description:Immunoediting sculpts immunogenicity and thwarts host anti-tumor responses in tumor cells during tumorigenesis; however, it remains unknown whether metabolic programming of tumor cells can be guided by immunosurveillance. Here, we report that T cell-mediated immunosurveillance in early staged tumorigenesis instructs c-Myc upregulation and metabolic reprogramming in tumor cells. This previously unexplored tumor-immune interaction is controlled by a non-canonical IFNg-STAT3 signaling and supports tumor immune evasion. Our findings uncover that immunoediting instructs deregulated bioenergetic programs in tumor cells for empowering them to disarm the T cell-mediated immunosurveillance by imposing metabolic tug-of-war between tumor and infiltrating T cells and forming the suppressive tumor microenvironment.

2022-11-15 | GSE217862 | GEO